RARE · ISSUER CIK 1515673
Ultragenyx Pharmaceutical Inc.
Between Aug 1, 2026 and Oct 29, 2026, 3 Ultragenyx Pharmaceutical Inc. insiders reported $0.00 of open-market purchases and $292K of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 3 of 5 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$292KInsider selling
−$292KNet open-market
Oct 19, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 202613:48 | Oct 15, 2026 | RARE | Chief Financial Officer | S · Sell | $15.27 | −7,066 | 89,229 | -7% | −$108K | ||
| Sep 15, 202618:57 | Sep 15, 2026 | RARE | SVP, Chief Accounting Officer | S · Sell10b5-1 | $13.57 | −1,283 | 67,863 | -2% | −$17K | ||
| Sep 8, 202612:29 | Sep 3, 2026 | RARE | SVP, Chief Accounting Officer | S · SellLate 5d | $13.99 | −161 | 69,146 | -0% | −$2K | ||
| Aug 4, 202615:15 | Aug 3, 2026 | RARE | EVP and Chief Legal Officer | S · Sell10b5-1 | $24.92 | −1,900 | 92,562 | -2% | −$47K | ||
| Aug 4, 202615:13 | Aug 3, 2026 | RARE | Chief Financial Officer | S · Sell10b5-1 | $24.92 | −4,696 | 96,295 | -5% | −$117K |